Compare JTAI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JTAI | BGLC |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 10.1M |
| IPO Year | N/A | N/A |
| Metric | JTAI | BGLC |
|---|---|---|
| Price | $1.19 | $4.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 120.9K | ★ 201.9K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,584,279.00 | $9,465,006.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $433.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $1.15 | $2.01 |
| 52 Week High | $11.77 | $15.60 |
| Indicator | JTAI | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 26.44 | 36.71 |
| Support Level | $1.15 | $4.05 |
| Resistance Level | $1.69 | $4.34 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 3.37 | 16.71 |
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.